Clinical Trial Update: Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, pharmacodynamics, and efficacy of KRN23 in children aged 1 to 4 with X-linked hypophosphatemia; the trial is completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Hypophosphatemia

Drugs mentioned

• KRN23 (burosumab)

Snippet

Sponsor: Kyowa Kirin, Inc. | Conditions: X-Linked Hypophosphatemia | Phase 2 | Status: COMPLETED | Results posted: 2018-06-19